• Original article (Basic research) • Previous Articles     Next Articles

Experimental study on effects of magnesium isoglycyrrhizinate on immune function of monocytes of patients with autoimmune hepatitis

LIN Rui, ZHOU Lu, ZHANG Jie, WANG Bang-mao, JIN Yang   

  1. Department of Gastroenterology, General Hospital, Tianjin Medical University, Tianjin 300052, China
  • Online:2014-08-28 Published:2014-09-02
  • Supported by:

    TianQing Liver Disease Research Fund Subject of Chinese Foundation for Hepatitis Prevention and Control, TQGB2011016

Abstract:

Objective To investigate the effects of magnesium isoglycyrrhizinate on the phagocytic ability and antigen presentation of monocytes of patients with auimmune hepatitis (AIH). Methods Peripheral blood mononuclear cells (PBMCs) of AIH patients (the AIH group) and health controls (the control group) were isolated by the density gradient centrifugation, cultured in vitro, and treated by magnesium isoglycyrrhizinate of different concentrations for 24 h. The percentage of HLA-DR+
cell and CD80+ cell was detected by the flow cytometry. PBMCs separated and purified by the CD14 monoclonal antibody beads were cultured with fluorescein isothiocyanate (FITC) labeled Escherichia coli. The phagocytosis rate and index were observed by the fluorescence microscopy, calculated, and confirmed by the flow cytometry. Results Compared to the control group, the percentage of HLA-DR+ cell and CD80+ cell, phagocytosis rate, and phagocytosis index of PBMCs of the AIH group (not treated by magnesium isoglycyrrhizinate) were significantly lower and the differences were statistically significant (P<0.01). In control group, the percentage of HLA-DR+ cell and CD80+ cell, phagocytosis rate, and phagocytosis index of PBMCs of the AIH group (treated by magnesium isoglycyrrhizinate) were higher than those of the blank group, but the differences were not statistically significant (P>0.05). In AIH group, the percentage of HLA-DR+ cell and CD80+ cell, phagocytosis rate, and phagocytosis index of PBMCs of the AIH group (treated by magnesium isoglycyrrhizinate of 1 and 10 mg/mL) were significantly higher than those of the blank group and the differences were statistically significant (P<0.01). Conclusion Magnesium isoglycyrrhizinate can improve the weakened phagocytic ability and antigen presentation of monocytes of patients with AIH, which indicates that magnesium isoglycyrrhizinate can regulate the immune function of monocytes of patients with AIH.

Key words: autoimmune hepatitis, magnesium isoglycyrrhizinate, monocytes, phagocytic function, antigen presentation